Irmukin 80 mg (Tablet)
Unit Price: ৳ 425.00 (3 x 10: ৳ 12,750.00)
Strip Price: ৳ 4,250.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Osimertinib |
| Company | Genvio pharma ltd |
Title
- Irmukin
Categories
- Medicine
- Pharmaceutical
Description
- Osimertinib is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
- Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) at approximately 9-fold lower concentrations than wild-type.
- The recommended dose of Osimertinib is 80 mg tablet once a day until disease progression or unacceptable toxicity.
- Most common adverse reactions (≥20%) were diarrhea, rash, dry skin, nail toxicity, stomatitis, fatigue and decreased appetite.
- Osimertinib can cause fetal harm when administered to a pregnant woman. There are no available data on Osimertinib use in pregnant women.
- Avoid concomitant administration of Irmukin with strong CYP3A inhibitors, including macrolide antibiotics (e.g., Telithromycin), antifungals (e.g., Itraconazole), antivirals (e.g., Ritonavir), Nefazodone, as concomitant use of strong CYP3A inhibitors may increase Irmukin plasma concentrations.
Attributes
- Metastatic non-small cell lung cancer (NSCLC) treatment
- Epidermal growth factor receptor (EGFR) exon 19 deletions detection
- Exon 21 L858R mutations detection
- Kinase inhibitor
- Irreversible binding
- Recommended dosage: 80mg tablet once a day
- Adverse reactions: diarrhea, rash, dry skin, nail toxicity, stomatitis, fatigue, decreased appetite
- Fetal harm potential in pregnant women
- Strong CYP3A inhibitors interaction
- Cytotoxic Chemotherapy therapeutic class
- Storage below 30°C
- Protection from moisture & light
- Dispersible tablet
- Fertility impairment potential
- Effective contraception advice for reproductive potential females and males
- Pediatric use not established
- Geriatric use observation
- Renal impairment dosage adjustment
- Hepatic impairment dosage recommendation
- Usable with or without food
- Missed dose instruction
- Dosage adjustment for adverse reactions
- Interactive with electrocardiograms and electrolytes monitoring
- Left ventricular ejection fraction (LVEF) assessment
- Contraindicated with strong CYP3A inducers
- Sensitive substrates of CYP3A interaction
- Pregnancy and lactation precautions
- Precaution for interstitial lung disease (ILD)/pneumonitis
- QTc interval prolongation monitoring
- Usable via nasogastric tube
- Usable in age, sex, ethnicity, body weight variations
- Usable in renal impairment variations
- Usable in hepatic impairment variations
- Usable in end-stage renal disease undetermined
- Usable in severe hepatic impairment undetermined
- Usable in conditions with no alternative
- Usable in patients with EGFR T790M mutation-positive NSCLC
- Usable in patients with metastatic EGFR T790M mutation-positive NSCLC
- Usable in patients whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy
- Usable in patients with NSCLC lines harboring EGFR-mutations
- Usable in patients with strong CYP3A inhibitors concomitant use
- Usable in patients with CYP3A inducers concomitant use
- Usable in patients with drugs sensitivities to CYP3A, BCRP, or CYP1A2
- Usable in patients with narrow therapeutic indices drugs